“Wait, What” TV Commercial :60 Seconds
Download this video to play in your office to educate your patients about VUITY®. The video must be played in its entirety and can’t be modified.
For US Healthcare Professionals Only
Download this video to play in your office to educate your patients about VUITY®. The video must be played in its entirety and can’t be modified.
Get highlighted access and
how-to-prescribe information from this handy one-page flashcard.
This flashcard helps you identify appropriate patient types for VUITY®.
Download this video to play in your office to educate your patients about VUITY™. The video must be played in its entirety and can’t be modified.
DownloadGet highlighted access and
how-to-prescribe information from this handy one-page flashcard.
This flashcard helps you identify appropriate patient types for VUITY®.
DownloadThis flashcard provides patients instructions for getting their prescription at home via UpScript Pharmacy.
VUITY® contracts the iris sphincter muscle, constricting the pupil to improve near and intermediate visual acuity while maintaining some pupillary response to light.1 VUITY® also contracts the ciliary muscle, and may shift the eye to a more myopic state.1
Please see the results from the GEMINI 1 and GEMINI 2 clinical trials.
VUITY® (pilocarpine hydrochloride ophthalmic solution) 1.25% is indicated for the treatment of presbyopia in adults.
VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.
Miotics, including VUITY, may cause accommodative spasm. Patients should be advised not to drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics, including VUITY. Patients should be advised to exercise caution in night driving and other hazardous activities in poor illumination.
Rare cases of retinal detachment and retinal tear have been reported with miotics, including VUITY. Individuals with pre-existing retinal disease are at increased risk. Therefore, examination of the retina is advised in all patients prior to the initiation of therapy. Patients should be advised to seek immediate medical care with sudden onset of flashing lights, floaters, or vision loss.
VUITY is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and lens.
Contact lens wearers should be advised to remove their lenses prior to the instillation of VUITY and to wait 10 minutes after dosing before reinserting their contact lenses.
To prevent eye injury or contamination, care should be taken to avoid touching the dispensing bottle to the eye or to any other surface.
The most common adverse reactions (>5%) reported in clinical trials were headache, conjunctival hyperemia, and eye irritation.
Please see full Prescribing Information.
US-VUI-230052
Reference: 1. VUITY [package insert]. North Chicago, IL: AbbVie Inc.